Logo

Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Share this

Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Shots:

  • NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs
  • The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology
  • FIND-IO platform has ability to identify cell surface molecular interactions while converting them into disease modifying immunotherapies

Ref: Eli Lilly | Image: Eli Lilly


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions